Venture Capital

As tech IPOs stall, a new breed of private credit fund offers a lifeline to employees with 'paper wealth,' unlocking billions in value from top unicorns.

TAE Technologies hires an Exxon Mobil veteran to build its first fusion plant, but a bizarre, unconfirmed merger claim with Trump's media group raises eyebrows.

With a new $400M debt facility, Dyne Therapeutics is accelerating two promising drugs for DMD and DM1, showcasing the power of strategic, non-dilutive financing.

With a promising drug and a fortified war chest, Trevi Therapeutics’ upcoming conference tour is a calculated move to conquer a vast, unmet medical need.

A return to profit and a 4.6p special dividend signal success for Octopus AIM VCT. But a deeper look reveals a masterclass in strategic exits and a VCT sector at a crossroads.

A Burkinabe court nullified a key stream deal, but Franco-Nevada says Ontario law governs. The dispute is a flashpoint for geopolitical risk.

Mastercard's $10,000 grants are just the headline. The real story is the ecosystem it's building to fix a broken funding model for women entrepreneurs.

The G7 unveils a plan to replace traditional aid with 'mutually beneficial partnerships.' But can this ambitious overhaul fix a broken system and tame a debt storm?

Medincell's latest results show a planned loss but reveal a strategic shift to recurring royalties, fueled by UZEDY®'s success and a pipeline set for growth.

A forgotten corner of oncology is set for a 14.2% CAGR. A new wave of drugs for chemo-induced neuropathy signals a major market realignment.

A new transatlantic force in financial services M&A is born as UK's Fenchurch merges with US fintech specialist Broadhaven, creating a 110-banker powerhouse.

With a novel non-hallucinogenic drug, Enveric Biosciences heads to the BIO convention seeking partners. Can its unique science secure its future?

With the hire of Patrick Duffy, Dropzone AI signals a major push in its mission to solve cybersecurity's twin crises with a new breed of AI agents.

With veteran investor Travis Read as new President & COO, AmMax Bio signals a major push to accelerate its promising antibody-drug conjugate pipeline.

Oxford Financial Group's major Cincinnati expansion highlights a national trend: the strategic battle for top talent and regional dominance in wealth management.

Adial Pharmaceuticals pivots from addiction to inflammation, securing $32M and poaching Azora's leadership to drive its new ulcerative colitis drug, AT177.

New research reveals a stark divide: leaders prioritize R&D while the public and investors demand reinvestment in workers. Who will win the battle for AI's gains?

With $10M in funding, Magnitude launches an autonomous AI workforce to combat machine-speed threats, forcing a reckoning in third-party risk management.

Tiny biotech HCW Biologics reports promising early data for its alopecia drug. But with a small sample size and big pharma rivals, is this a true breakthrough?

With a major debt financing, French biotech Inventiva is funded through a pivotal Phase 3 trial for its MASH drug, highlighting a strategic shift in biotech funding.